logo-loader
/**/ p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .bh{size:595.3pt 841.9pt;margin:99.25pt 72.0pt 72.0pt 72.0pt;}div.bh{}p.dy{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";font-weight: bold; text-align: justify}span.dw{font-family:"Calibri","sans-serif"}p.dz{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";font-weight: bold; text-align: center}p.ea{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";text-align: center}p.eb{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";text-align:justify}span.ec{color: #212721; font-family: "Calibri","sans-serif"; font-weight: bold}span.ed{font-family:"Calibri","sans-serif";color:#212721}p.ee{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";margin-bottom:12.1pt;text-align:justify;line-height: 11.75pt} span.dp{color:#212721}table.ef{width:451.7pt;margin-left:-5.4pt;border-collapse:collapse}tr.dd{height:31.3pt}td.dm{width:61.35pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:31.3pt}p.eg{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 11.75pt; margin-bottom: 12.1pt; text-align: justify}span.dr{font-family:"Calibri","sans-serif";color:#212721}td.dk{width:117.55pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:31.3pt}p.eh{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 11.75pt; margin-bottom: 12.1pt}td.dh{width:88.2pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 0cm 0cm 0cm;height:31.3pt}p.ei{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 11.75pt; margin-bottom: 12.1pt; margin-left: 5.2pt; margin-right: 0cm; margin-top: 0cm} span.dj{font-family:"Calibri","sans-serif"; color:#212721}td.df{width:90.5pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 0cm 0cm 0cm;height:31.3pt}p.ej{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 11.75pt; margin-bottom: 12.1pt; margin-left: 3.0pt; margin-right: 0cm; margin-top: 0cm}td.de{width:72.5pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 0cm 0cm 0cm;height:31.3pt}tr.cu{height:23.1pt}td.db{width:61.35pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:23.1pt}p.ek{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";margin-bottom:12.1pt;line-height:11.75pt}td.da{width:117.55pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:23.1pt}td.cy{width:88.2pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 0cm 0cm 0cm;height:23.1pt}p.el{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";margin-top:0cm;margin-right:0cm;margin-bottom:12.1pt; margin-left:5.2pt;text-align:justify;line-height:11.75pt} td.cw{width:90.5pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 0cm 0cm 0cm;height:23.1pt}p.em{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";margin-top:0cm;margin-right:0cm;margin-bottom:12.1pt; margin-left:3.0pt;text-align:justify;line-height:11.75pt}td.cv{width:72.5pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 0cm 0cm 0cm;height:23.1pt}p.en{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: normal; margin-bottom: 10.0pt; text-align: justify}span.cs{font-family:"Calibri","sans-serif";color:black}p.eo{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";text-align:justify;line-height:normal}p.ep{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: normal; text-align: justify}p.eq{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";margin-bottom:10.0pt;text-align:justify;line-height: normal}span.co{font-family:"Calibri","sans-serif"; color:black}p.er{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;text-align:justify} span.cm{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}p.es{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm}span.ck{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}span.et{color:#0563C1;text-decoration:underline;font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.eu{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: normal; text-align: center}p.ev{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 11.75pt; margin-bottom: 12.1pt; text-align: center}table.ew{width:451.3pt;margin-left:-9.0pt;border-collapse:collapse}td.cf{border:solid black 1.0pt;padding:1.2pt 1.2pt 1.2pt 3.0pt}td.ce{border:solid black 1.0pt;border-left:none; padding:1.2pt 1.2pt 1.2pt 3.0pt}td.cd{border:solid black 1.0pt;border-top:none;padding:1.2pt 1.2pt 1.2pt 3.0pt} td.cc{width:173.1pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt}td.cb{width:248.05pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt}td.ca{border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:1.2pt 1.2pt 1.2pt 3.0pt}td.bz{border-top:none;border-left:none;border-bottom:solid black 1.0pt; border-right:solid black 1.0pt;padding:1.2pt 1.2pt 1.2pt 3.0pt}p.ex{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";font-div: italic; line-height: 11.75pt; margin-bottom: 12.1pt; text-align: justify}table.ey{width:216.4pt;border-collapse:collapse}tr.bv{height:22.2pt}td.bx{border:solid black 1.0pt;padding:1.2pt 1.2pt 1.2pt 3.0pt; height:22.2pt}td.bw{border:solid black 1.0pt;border-left:none;padding: 1.2pt 1.2pt 1.2pt 3.0pt;height:22.2pt}tr.br{height:27.1pt} td.bt{border-top:none;border-left:solid black 1.0pt; border-bottom:none;border-right:solid black 1.0pt;padding:1.2pt 1.2pt 1.2pt 3.0pt; height:27.1pt}p.ez{margin:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Cambria","serif";margin-bottom:12.1pt;text-align:justify; line-height:11.75pt}td.bs{border:none;border-right:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt;height:27.1pt}table.fa{width:216.45pt;border-collapse:collapse}tr.bn{height:23.0pt}td.bp{width:146.55pt;border:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt;height:23.0pt}td.bo{width:53.1pt;border:solid black 1.0pt; border-left:none;padding:1.2pt 1.2pt 1.2pt 3.0pt;height:23.0pt}tr.bk{height:23.85pt}td.bm{width:146.55pt;border:solid black 1.0pt; border-top:none;padding:1.2pt 1.2pt 1.2pt 3.0pt;height:23.85pt}td.bl{width:53.1pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt;height:23.85pt} /**/
RNS Number : 8711V
C4X Discovery Holdings PLC
05 December 2019
 

 

C4X Discovery Holdings plc

("C4XD" or the "Company")

 

GRANT OF OPTIONS AND DIRECTORS DEALING

 

5 December 2019 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces today that a total of 750,000 options over ordinary shares of the Company were awarded pursuant to the EMI 2014 Plan to certain employees, which includes 250,000 options each to Dr Clive Dix, Chief Executive Officer, Dr Craig Fox, Chief Scientific Officer and Brad Hoy, Chief Financial Officer, as set out below.

 

Director

Position

Number of share options awarded

Option exercise price per share (pence)

Total number of options held

Dr Clive Dix

Chief Executive Officer

250,000

16.2

445,000

Dr Craig Fox

Chief Scientific Officer        

250,000

16.2

500,000

Brad Hoy

Chief Financial Officer                                   

250,000

16.2

600,000

 

The options have an exercise price of 16.2p, being the average 5-day VWAP of the Ordinary Shares to the 29 November 2019. The options can be exercised at any time between 3 years and 10 years of them being granted.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

For further information, please contact:

C4X Discovery Holdings plc

Clive Dix, Chief Executive Officer                                                                                                            07801 865 803

 

Panmure Gordon (UK) Limited (NOMAD)                                                                                          020 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)                                                                                              

James Stearns (Corporate Broking)                                                                                                                         

 

Consilium Strategic Communications

Mary-Jane Elliott, Matthew Neal, Chris Gardner                                                                                0203 709 570

About C4X Discovery

 

C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.

C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

For additional information please go to: www.c4xdiscovery.com 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Clive Dix

2

Reason for the notification


a)


Position/status

 

Chief Executive Officer, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

C4X Discovery Holdings plc

b)

LEI

213800UHNL82E323O870

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code
 

Options over 1p Ordinary Shares - EMI 2014 Plan 

 

ISIN GB00BQQ2RV18

b)

Nature of the transaction

 

Grant of Options over Ordinary Shares

c)

Price(s) and volume(s)

 

 

Price(s) per Ordinary Share

Volume(s)

16.2p

250,000

 

d)

Aggregated information

 

Price

Volume(s)

N/A

N/A

 

e)

Date of the transaction

 

29 November 2019

f)

Place of the transaction

 

 

London Stock Exchange - AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Craig Fox

2

Reason for the notification


a)


Position/status

 

Chief Scientific Officer, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

C4X Discovery Holdings plc

b)

LEI

213800UHNL82E323O870

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code
 

Options over 1p Ordinary Shares - EMI 2014 Plan 

 

ISIN GB00BQQ2RV18

b)

Nature of the transaction

 

Grant of Options over Ordinary Shares

c)

Price(s) and volume(s)

 

 

Price(s) per Ordinary Share

Volume(s)

16.2p

250,000

 

d)

Aggregated information

 

Price

Volume(s)

N/A

N/A

 

e)

Date of the transaction

 

29 November 2019

f)

Place of the transaction

 

 

London Stock Exchange - AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Brad Hoy

2

Reason for the notification


a)


Position/status

 

Chief Financial Officer, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

C4X Discovery Holdings plc

b)

LEI

213800UHNL82E323O870

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code
 

Options over 1p Ordinary Shares - EMI 2014 Plan 

 

ISIN GB00BQQ2RV18

b)

Nature of the transaction

 

Grant of Options over Ordinary Shares

c)

Price(s) and volume(s)

 

 

Price(s) per Ordinary Share

Volume(s)

16.2p

250,000

 

d)

Aggregated information

 

Price

Volume(s)

N/A

N/A

 

e)

Date of the transaction

 

29 November 2019

f)

Place of the transaction

 

 

London Stock Exchange - AIM

 

Name of authorised official of issuer responsible for making notification: Brad Hoy, Chief Financial Officer of the Company.

--ENDS-

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHUVUSRKUAURAA

Quick facts: C4X Discovery Holdings PLC

Price: 12

Market: AIM
Market Cap: £13 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: C4X Discovery fully cashed up and sees big potential for its...

C4X Discovery Holdings plc's (LON:C4XD) Clive Dix speaks to Proactive London's Andrew Scott following the news they've raised around £6.6mln to strengthen its balance sheet amid ongoing licensing discussions for its early-stage drug candidates. While expressing regret for the level at which...

on 25/10/19